600276.SH
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 46.76
−2.05%Price chart
Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18
Key dataSep 18, 2026
OpenCNY 43.52
From 52W high−35.48%
Volume56.93M
Market capCNY 310.36B
P/E (TTM)40.3x
P/S (TTM)8.9x
Div yield0.46%
Key dataSep 18, 2026
Open
CNY 43.52
From 52W high
−35.48%
Volume
56.93M
Market cap
CNY 310.36B
ValuationView details →
P/E (Fwd)
32.4x
EV/EBITDA
25.4x
P/E (TTM)
40.3x
RSI (14)
34.7
MomentumView details →
1D Return
−2.05%
YTD Return
−26.29%
Similar companies
Latest newsMore news →
Hengrui Pharmaceuticals reported R&D spending of 4.605 billion yuan in the first half of 2026, up 18.96% year on year and equal to 29.8% of revenue.6h agoHengrui Pharmaceuticals reported that in the first half of 2026 its innovative-drug sales revenue rose to 8.809 billion yuan, 63.16% of drug sales revenue, with non-oncology innovative-drug revenue up 73.97%.6h agoHengrui Pharmaceuticals received Chinese approval in 2026 for four Class 1 innovative drugs — rilafusp alfa injection, luzonorestat sodium tablets, insulin sudi injection and fumurate likangcopan capsules — plus the Class 2 new drug cyclosporine eye drops (IV).6h ago